Vertex Gains In Vivo CRISPR Foothold With Mammoth Pact

 
• By Alaric DeArment
DNA detail background with selective focus
Mammoth and Vertex entered a deal worth nearly $700m for in vivo gene-edited therapies • Source: Shutterstock

More from Archive

More from Scrip